期刊文献+

对氧磷酶-3和糖氧化载脂蛋白A-I与糖尿病并发冠心病的关系 被引量:6

The Association of PON3 and Glycoxidative apoA-I with Type 2 Diabetes Complicated with Coronary Artery Disease
下载PDF
导出
摘要 目的:探讨血清对氧磷酶-3(PON3)和载脂蛋白A-I(apoA-I)糖氧化水平与2型糖尿病(T2DM)并发冠心病(CAD)及其严重程度的关系。方法:202例T2DM患者按其是否合并CAD分为单纯糖尿病组(DM组,n=60)和T2DM合并CAD组(DM并CAD组,n=142),后者进一步按病变累及冠脉支数分为1支病变组(n=40),2支病变组(n=52)和3支病变组(n=50)。另选62例健康受试者为对照组。采用ELISA测定各组血清PON3水平;超速离心全血获得高密度脂蛋白(HDL),采用SDS-PAGE电泳分离apoA-I,免疫印迹分析apoA-I糖氧化水平。分析PON3水平和apoA-I糖氧化水平与冠脉病变程度的相关性。结果:DM并CAD组和3支病变组血清PON3水平(1.52±1.14ng/ml、1.31±1.09ng/ml)分别显著低于DM组(1.98±1.04ng/ml,P<0.05)、对照组(2.46±1.01ng/ml,P<0.05)和1支病变组(1.74±1.19ng/ml,P<0.05)。apoA-I糖氧化水平是CAD及其病变严重程度的独立预测因子,并与冠脉病变严重程度指数、病变冠脉支数呈显著正相关(r分别为0.611、0.549,P均<0.01)PON3水平与apoA-I糖氧化水平呈负相关(r=-0.388,P<0.01),且两者均为CAD独立预测因素。结论:低PON3水平与apoA-I糖氧化水平相关,后者与T2DM患者并发CAD及其严重程度相关。 Objective:To explore the association of serum paraoxonase-3 (PON3 )and glycoxidative apoA-I levels with type 2 diabetes(T2DM)complicated with coronary artery disease(CAD).Method:202 T2DM patients were divided into T2DM without CAD group (n=60)and T2DM with CAD group(n=142),the latter was further classified with respect to the number of diseased coronary arteries as 1-vessel disease group(n=40),2-vessel disease group (n=52)and 3-vessel disease group(n=50),62 healthy subjects were served as control group.Serum PON3 levels were measured with ELISA.HDL proteins after ultracentrifugation were separated by SDS-polyacrylamide. Glycoxidative levels of apoA-I were analyzed by Western blot.Results:Serum PON3 levels were significantly lower in T2DM with CAD group (1.52±1.14ng/ml)and in patients with 3-vessel disease (1.31±1.09ng/ml)than those in T2DM)without CAD group (1.98±1.04ng/ml,P〈0.05)and controls (2.46±1.01ng/ml,P〈0.05)and 1-vessel disease group (1.74±1.19ng/ml,P〈0.05),respectively.Glycoxidative level of apoA-I was an independent risk factor for the presence and severity of CAD,and positively correlated with QCA-derived extent index (Pearson’s,r=0.611),the number of diseased coronary arteries (Spearman’s,r=0.549),all P〈0.01),respectively.Serum&amp;nbsp;PON3 level was negatively correlated with glycoxidative level of apoA-I(Pearson’s,r=-0.388,P〈0.01),both were independently associated with the presence of CAD.Conclusion:Reduced level of PON3 is associated with glycoxi-dative level of apoA-I.apoA-I glycoxidative level is associated with the presence and severity of CAD in T2DM patients.
出处 《微循环学杂志》 2014年第4期20-25,共6页 Chinese Journal of Microcirculation
关键词 对氧磷酶-3 载脂蛋白A-1 糖尿病 冠心病 相关性 Paraoxonase-3 Apolipoprotein A-I Diabetes mellitus disease Coronary artery disease Relation
  • 相关文献

参考文献13

  • 1Pu LJ,Lu L,Zhang RY,et al.Glycation of apoprotein A-I is associated with coronary artery plaque progression in type 2diabetic patients[J].Diabetes Care,2013,36(5):1 312-1 320.
  • 2Kontush A,Chapman MJ.Why is HDL functionally deficient in type 2diabetes[J].Curr Diab Rep,2008,8(1):51-59.
  • 3Rajkovic MG,Rumora L,Barisic K.The paraoxonase 1,2and 3in humans[J].Biochem Med(Zagreb),2011,21(2):122-130.
  • 4Aviram M,Rosenblat M,Bisgaier CL,et al.Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions.A possible peroxidative role for paraoxonase[J].J Clin Invest,1998,101(8):1 581-1 590.
  • 5Expert committee on the diagnosis and classification of diabetes mellitus.Report of the expert committee on the diagnosis and classification of diabetes mellitus[J].Diabetes Care,2003,26(Suppl 1):S5-20.
  • 6Lu L,Pu LJ,Zhang Q,et al.Increased glycated albumin and decreased esRAGE levels are related to angiographic severity and extent of coronary artery disease in patients with type 2diabetes[J].Atherosclerosis,2009,206(2):540-545.
  • 7Mackness MI,Walker CH."A"-esterase activity in the lipoprotein fraction of sheep serum[J].Biochem Pharmacol,1981,30(8):903-906.
  • 8Luhtala N,Parker R.LSM1over-expression in Saccharomyces cerevisiae depletes U6snRNA levels[J].Nucleic Acids Res,2009,37(16):5 529-5 536.
  • 9Nobecourt E,Davies MJ,Brown BE,et al.The impact of glycation on apolipoprotein A-I structure and its ability to activate lecithin:cholesterol acyltransferase[J].Diabetologia,2007,50(3):643-653.
  • 10Anderson MM,Requena JR,Crowley JR,et al.The myeloperoxidase system of human phagocytes generates Nepsilon-(carboxymethyl)lysine on proteins:a mechanism for producing advanced glycation end products at sites of inflammation[J].J Clin Invest,1999,104(1):103-113.

同被引文献38

  • 1陈懿,徐世鄂.瑞舒伐他汀和阿托伐他汀对冠心病患者的调脂作用和安全性比较[J].中国老年学杂志,2014,34(9):2389-2390. 被引量:93
  • 2王青山.阿托伐他汀联合曲美他嗪治疗冠心病的疗效[J].中国老年学杂志,2014,34(10):2743-2744. 被引量:78
  • 3Stienstra R,Tack CJ,Kanneganti TD,et al.The inflammasome puts obesity in the danger zone[J].Cell Metab,2012,15(1):10-18.
  • 4Wen H,Ting JP,O'Neill LA.A role for the NLRP3inflammasome in metabolic diseases-did Warburg miss inflammation[J].Nat Immunol,2012,13(4):352-357.
  • 5Lee HM,Kim JJ,Kim HJ,et al.Upregulated NLRP3inflammasome activation in patients with type 2diabetes[J].Diabetes,2013,62(1):194-204.
  • 6Wang C,Pan Y,QY Z,et al.Quercetin and allopurinol ameliorate kidney injury in STZ-treated rats with regulation of renal NLRP3inflammasome activation and lipid accumulation[J].PLoS One,2012,7(6):e38285.
  • 7Luo B,Wang F,Li B,et al.Association of nucleotide-binding oligomerization domain-like receptor 3inflammasome and adverse clinical outcomes in patients with idiopathic dilated cardiomyopathy[J].Clin Chem Lab Med,2013,51(7):1 521-1 528.
  • 8Masters SL,Latz E,O'Neill LA.The inflammasome in atherosclerosis and type 2diabetes[J].Sci Transl Med,2011,3(1):81-98.
  • 9Schroder K,Tschopp J.The inflammasomes[J].Cell,2010,140(6):821-832.
  • 10De Nardo D,Latz E.NLRP3inflammasomes link inflammation and metabolic disease[J].Trends Immunol,2011,32(8):373-379.

引证文献6

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部